Prostaglandin E2 prevents hyperosmolar-induced human mast cell activation through prostanoid receptors EP2 and EP4

PLoS One. 2014 Oct 20;9(10):e110870. doi: 10.1371/journal.pone.0110870. eCollection 2014.

Abstract

Background: Mast cells play a critical role in allergic and inflammatory diseases, including exercise-induced bronchoconstriction (EIB) in asthma. The mechanism underlying EIB is probably related to increased airway fluid osmolarity that activates mast cells to the release inflammatory mediators. These mediators then act on bronchial smooth muscle to cause bronchoconstriction. In parallel, protective substances such as prostaglandin E2 (PGE2) are probably also released and could explain the refractory period observed in patients with EIB.

Objective: This study aimed to evaluate the protective effect of PGE2 on osmotically activated mast cells, as a model of exercise-induced bronchoconstriction.

Methods: We used LAD2, HMC-1, CD34-positive, and human lung mast cell lines. Cells underwent a mannitol challenge, and the effects of PGE2 and prostanoid receptor (EP) antagonists for EP(1-4) were assayed on the activated mast cells. Beta-hexosaminidase release, protein phosphorylation, and calcium mobilization were assessed.

Results: Mannitol both induced mast cell degranulation and activated phosphatidyl inositide 3-kinase and mitogen-activated protein kinase (MAPK) pathways, thereby causing de novo eicosanoid and cytokine synthesis. The addition of PGE2 significantly reduced mannitol-induced degranulation through EP(2) and EP(4) receptors, as measured by beta-hexosaminidase release, and consequently calcium influx. Extracellular-signal-regulated kinase 1/2, c-Jun N-terminal kinase, and p38 phosphorylation were diminished when compared with mannitol activation alone.

Conclusions: Our data show a protective role for the PGE2 receptors EP(2) and EP(4) following osmotic changes, through the reduction of human mast cell activity caused by calcium influx impairment and MAP kinase inhibition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asthma, Exercise-Induced / genetics
  • Asthma, Exercise-Induced / metabolism
  • Asthma, Exercise-Induced / pathology
  • Cell Degranulation*
  • Cell Line
  • Dinoprostone / genetics
  • Dinoprostone / metabolism*
  • Diuretics, Osmotic / pharmacology
  • Extracellular Signal-Regulated MAP Kinases / genetics
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Humans
  • Lung / metabolism
  • Lung / pathology
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / genetics
  • Mannitol / pharmacology
  • Mast Cells / metabolism*
  • Mast Cells / pathology
  • Osmotic Pressure*
  • Phosphatidylinositol 3-Kinases / genetics
  • Phosphatidylinositol 3-Kinases / metabolism
  • Receptors, Prostaglandin E, EP2 Subtype / genetics
  • Receptors, Prostaglandin E, EP2 Subtype / metabolism*
  • Receptors, Prostaglandin E, EP4 Subtype / genetics
  • Receptors, Prostaglandin E, EP4 Subtype / metabolism*

Substances

  • Diuretics, Osmotic
  • PTGER2 protein, human
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Mannitol
  • Phosphatidylinositol 3-Kinases
  • Extracellular Signal-Regulated MAP Kinases
  • Dinoprostone

Grants and funding

This work was supported by grants from the Plan Nacional Ministerio de Ciencia e Innovación (SAF2009-07548) and Fondo de Investigaciones Sanitarias, Ministerio de Economía y Competitividad, Spain (PI1200332). IT-A was the recipient of a doctoral studies scholarship from the Secretaria Nacional de Ciencia, Tecnología e Innovación SENACYT, Gobierno de la República de Panamá. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.